Obesity: The need for effective weight-loss solutions couldn’t come sooner.
As Novo Nordisk’s liraglutide is reviewed by the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) today (Scrip Intelligence 10/09/14), it is clear that the need for effective weight-loss solutions couldn’t come sooner.
Obesity is a global epidemic and doesn’t show signs of stopping: Datamonitor Healthcare epidemiologists have estimated that by 2030, there will be approximately 200 million obese individuals in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). On top of this, China and Brazil will account for more than 141 million additional cases of obesity.
Currently, the majority of obese patients are treated with physician-managed lifestyle changes such as diet and physical activity but the forecasted increases in patient populations across the world will place an unsustainable burden on weight management services and primary care systems. If left untreated, obese individuals will place an even greater strain on healthcare systems throughout the world through the treatment of co-morbidities and additional complications which are seen in the population.
Pharmaceutical treatment may provide a desperately needed solution to tackling obesity, and the increasing choice between available drugs gives physicians and patients an opportunity to tackle this condition effectively.
Posted in Metabolic.